In 1114 BC patients (stage in situ to IV), Nelson et al. reported that only patients with higher CRP levels and normal-weight had an increased risk of death (HR: 1.39 [95% CI = 1.03–1.89]) for every 1 standard deviation increase in logCRP21. The gene discussed is CRP; the disease is breast cancer.